Cited by 2,077Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index.

Epidemiology and risk profile of heart failure

Open access

Bui, Anh L., Horwich, Tamara B., Fonarow, Gregg C.·2011·Nature Reviews Cardiology

DOI 10.1038/nrcardio.2010.165PMC PMC3033496

Open this paper in CoChat — free account

Abstract

Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in five. Although promising evidence shows that the age-adjusted incidence of HF may have plateaued, HF still carries substantial morbidity and mortality, with 5-year mortality that rival those of many cancers. HF represents a considerable burden to the health-care system, responsible for costs of more than $39 billion annually in the USA alone, and high rates of hospitalizations, readmissions, and outpatient visits. HF is not a single entity, but a clinical syndrome that may have different characteristics depending on age, sex, race or ethnicity, left ventricular ejection fraction (LVEF) status, and HF etiology. Furthermore, pathophysiological differences are observed among patients diagnosed with HF and reduced LVEF compared with HF and preserved LVEF, which are beginning to be better appreciated in epidemiological studies. A number of risk factors, such as ischemic heart disease, hypertension, smoking, obesity, and diabetes, among others, have been identified that both predict the incidence of HF as well as its severity. In this Review, we discuss key features of the epidemiology and risk profile of HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrcardio.2010.165

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,824
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209 · cited 1×
“HF and preserved LVEF now represents >50% of HF cases and can have outcomes as poor as those associated with HF and reduced LVEF, but it does not yet have a proven effective management strategy”
Background
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
Swedberg, K. B., & KJEKSHUS, J. K. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652

Show all 144 references

Research works printed but not linked: 1

Gordis, L. Epidemiology 37–84 (Elsevier/Saunders, Philadelphia, 2009).

Sorted by citations

Items 601–700 of 1,002

Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016
Vuong, J. T., Jacob, S., Alexander, K. M., Singh, A., Liao, R., Desai, A. S., & Dorbala, S. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.11.012 · Cited by 28
Gelatin Methacryloyl Bioadhesive Improves Survival and Reduces Scar Burden in a Mouse Model of Myocardial Infarction
Ptaszek, L. M., Lara, R. P., Sani, E. S., Xiao, C., Roh, J. D., Yu, X., Ledesma, P. A., Yu, C. H., Annabi, N., & Ruskin, J. N. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014199 · Cited by 28
Sarcoplasmic reticulum calcium mishandling: central tenet in heart failure?
Denniss, A., Dashwood, A. M., Molenaar, P., & Beard, N. A. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00736-y · Cited by 28
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
Chambergo‐Michilot, D., Tauma‐Arrué, A., & Loli-Guevara, S. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100690 · Cited by 30
Sacubitril/Valsartan Ameliorates Cardiac Hypertrophy and Preserves Diastolic Function in Cardiac Pressure Overload
Nordén, E. S., Bendiksen, B. A., Andresen, H., Bergo, K. K., Espe, E. K. S., Hasic, A., Hauge‐Iversen, I. M., Veras, I., Hussain, R. I., Sjaastad, I., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13177 · Cited by 28
Exogenous extracellular matrix proteins decrease cardiac fibroblast activation in stiffening microenvironment through CAPG
Wang, X., Pierre, V., Liu, C., Senapati, S., Park, P. S. ‐., & Senyo, S. E. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.06.001 · Cited by 28
An Improved Auto Categorical PSO with ML for Heart Disease Prediction
Dubey, A. K., Sinhal, A. K., & Sharma, R. (2022) · Engineering Technology & Applied Science Research · doi:10.48084/etasr.4854 · Cited by 28
“I NTRODUCTION Globally, many people suffer from heart diseases [1].”
Background
Heart failure family-based education: a systematic review
Srisuk, N., Cameron, J., Ski, C. F., & Thompson, D. R. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.10.009 · Cited by 30
“Heart failure (HF) is a major chronic health problem [1] associated with high rates of mortality [2], symptom burden [3], rehospitalisation [4] and diminished quality of life [5].”
Background
Characterization of the ultrashort‐TE (UTE) MR collagen signal
Siu, A. G., Ramadeen, A., Hu, X., Morikawa, L., Zhang, L., Lau, J. Y. C., Liu, G., Pop, M., Connelly, K. A., Dorian, P., et al. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3372 · Cited by 28
Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure
Mazziotti, G., Baracca, M., Doga, M., Porcelli, T., Vescovi, P. P., & Giustina, A. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0566 · Cited by 28
Resting Heart Rate and Long-term Outcomes Among the African American Population
Parikh, K. S., Greiner, M. A., Suzuki, T., DeVore, A. D., Blackshear, C. T., Maher, J., Curtis, L. H., Hernandez, A. F., O'Brien, E. C., & Mentz, R. J. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3234 · Cited by 29
Rupture of sinus of Valsalva aneurysm: Two case reports and a concise review of the literature
Marroush, T. S., Boshara, A. R., Botros, B., Vendittelli, P., Ahmed, Z., Dawood, L., & Rosman, H. (2017) · Heart & Lung · doi:10.1016/j.hrtlng.2017.10.005 · Cited by 28
Autologous c‐Kit+ Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to c‐Kit+ Cardiac‐Derived Stem Cells in a Feline Model of Isoproterenol‐Induced Cardiomyopathy
Taghavi, S., Sharp, T. E., Duran, J. M., Makarewich, C. A., Berretta, R. M., Starosta, T., Kubo, H., Barbe, M. F., & Houser, S. R. (2015) · Clinical and Translational Science · doi:10.1111/cts.12251 · Cited by 27
Predictors of Delay in Heart Failure Patients and Consequences for Outcomes
Sethares, K. A., Chin, E. D., & Jurgens, C. Y. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0241-5 · Cited by 27
Sacubitril-Valsartan for the Treatment of Heart Failure
Ollendorf, D. A., Sandhu, A. T., & Pearson, S. D. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7661 · Cited by 27
“Key roundtable recommendations included (1) restricting prescribing to cardiologists to best monitor and manage adverse effects during the transition to sacubitril-valsartan; and (2) prioritizing use of sacubitril-valsartan in younger patients better able to tolerate a change in therapy, patients with worsening diseas…”
Background
Subclinical Cardiac Dysfunction in Obesity Patients is Linked to Autonomic Dysfunction: Findings from the CARDIOBESE Study
Snelder, S. M., Laat, L. E. D. G., Biter, L. U., Cabezas, M. C., Pouw, N. M. C., Birnie, E., Klerk, B. M. B., Klaassen, R. A., Zijlstra, F., & van Dalen, B. M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12942 · Cited by 28
“The association between abnormalities in cardiac structure and function is known in obesity patients.(1) Because of the ongoing obesity epidemic, efficient screening for (subclinical) cardiac dysfunction in these patients is needed.”
Background
Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?
Raffaello, W. M., Henrina, J., Huang, I., Lim, M. A., Suciadi, L. P., Siswanto, B. B., & Pranata, R. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.20 · Cited by 30
ChatGPT and Patients With Heart Failure
Dimitriadis, F., Alkagiet, S., Tsigkriki, L., Kleitsioti, P., Sidiropoulos, G., Efstratiou, D., Askalidi, T., Tsaousidis, A., Siarkos, M., Giannakopoulou, P., et al. (2024) · Angiology · doi:10.1177/00033197241238403 · Cited by 27
Simple Measures of Function and Symptoms in Hospitalized Heart Failure Patients Predict Short-Term Cardiac Event-Free Survival
Zaharias, E., Cataldo, J. K., Mackin, L. A., & Howie‐Esquivel, J. (2014) · Nursing Research and Practice · doi:10.1155/2014/815984 · Cited by 27
“Despite current medical treatment, the prognosis for HF is poor, with a 5-yearmortality rate of 45–60% [2].”
BackgroundInfluential
Outcomes of Multiple Listing for Adult Heart Transplantation in the United States
Givens, R. C., Dardas, T., Clerkin, K. J., Restaino, S. W., Schulze, P. C., & MANCINI, D. M. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.07.012 · Cited by 28
“Introduction Severe heart failure is an increasingly prevalent public health problem (1).”
Background
Predictors of Rehospitalization in Patients Admitted With Heart Failure in Abeokuta, Nigeria: Data From the Abeokuta Heart Failure Registry
Ogah, O. S., Stewart, S., Falase, A. O., Akinyemi, J. O., Adegbite, G. D., Alabi, A. A., Ajani, A. A., Adesina, J. O., Durodola, A., & Sliwa, K. S. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.08.012 · Cited by 27
“Heart failure (HF) affects O23 million people worldwide.(1) In the United States alone, w5.”
Oxygen consumption of human heart cells in monolayer culture
Sekine, K., Kagawa, Y., Maeyama, E., Ota, H., Haraguchi, Y., Matsuura, K., & Shimizu, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.018 · Cited by 27
The relationship between sweetened beverage consumption and risk of heart failure in men
Rahman, I., Wolk, A., & Larsson, S. C. (2015) · Heart · doi:10.1136/heartjnl-2015-307542 · Cited by 28
Dyadic incongruence in chronic heart failure: Implications for patient and carer psychological health and self‐care
Cameron, J., Thompson, D. R., Szer, D., Greig, J., & Ski, C. F. (2017) · Journal of Clinical Nursing · doi:10.1111/jocn.13836 · Cited by 27
“Chronic heart failure (CHF), a complex and changeable condition, affects around 23 million people worldwide and its prevalence increases with age (Bui et al. 2011).”
Background
Identification of active components in Yixinshu Capsule with protective effects against myocardial dysfunction on human induced pluripotent stem cell-derived cardiomyocytes by an integrative approach
Zhang, M., Wu, H., Guo, F., Yu, Y., Wei, J., Geng, Y., Wang, S., Li, S., & Yang, H. (2017) · Molecular BioSystems · doi:10.1039/c6mb00813e · Cited by 27
Effect of Hospital Ownership on Outcomes of Heart Failure Hospitalization
Akintoye, E. O., Briasoulis, Α., Egbe, A. C., Orhurhu, V., Ibrahim, W., Kumar, K. R., Alliu, S., Nas, H., Levine, D., & Weinberger, J. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.009 · Cited by 27
“Despite advances in therapy and management, heart failure continues to pose a significant public health challenge as a major cause of morbidity and mortality.(1,2) It is therefore imperative to identify areas of improvement in this patient population.”
Background
Sex-Specific Disparities in Risk Factors for Coronary Heart Disease
Rosen, S. E., Henry, S. A., Bond, R. M., Pearte, C. A., & Mieres, J. H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0523-8 · Cited by 26
Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis
Wang, X., Zhu, D., & Shan, Y.-X. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0134-3 · Cited by 27
“8 million new cases of HF are reported annually, and HF affects over 23 million individuals annually worldwide [4, 5].”
Background
Cardiac Depression Scale: Mokken scaling in heart failure patients
Ski, C. F., Thompson, D. R., Hare, D. L., Stewart, A. G. O., & Watson, R. A. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-141 · Cited by 26
“Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide that imposes a considerable human and economic burden [1-4].”
Background
Expert Comment: Is Medication Titration in Heart Failure too Complex?
Atherton, J. J., & Hickey, A. (2017) · Cardiac failure review · doi:10.15420/cfr.2017:1:2 · Cited by 26
Involvement of oxidative modification of proteins related to ATP synthesis in the left ventricles of hamsters with cardiomyopathy
Ichihara, S., Suzuki, Y., Chang, J., Kuzuya, K., Inoue, C., Kitamura, Y., & Oikawa, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08546-1 · Cited by 27
Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging
van Leenders, G. J. L. H., Smeets, M. B., van den Boomen, M., Berben, M., Nabben, M., van Strijp, D., Strijkers, G. J., Prompers, J. J., Arslan, F., Nicolay, K., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310339 · Cited by 26
Gender Differences in Utilization of Specialized Heart Failure Clinics
Abrahamyan, L., Sahakyan, Y., Wijeysundera, H. C., Krahn, M. D., & Rac, V. E. (2018) · Journal of Women s Health · doi:10.1089/jwh.2017.6461 · Cited by 26
The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review
Baniaamam, M., Paulus, W. J., Blanken, A. B., & Nurmohamed, M. T. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1462794 · Cited by 26
“Early recognition of CHF in RA patients is important as these patients have increased risk for mortality and comorbidity [34].”
Background
Heart failure self-management and normalizing symptoms: an exploration of decision making in the community
Schumacher, C., Hussey, L. C., & Hall, V. P. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.03.013 · Cited by 26
Effects of combined aerobic and resistance training in patients with heart failure: A meta‐analysis of randomized, controlled trials
Wang, Z., Peng, X., Li, K., & Wu, C.-J. J. (2019) · Nursing and Health Sciences · doi:10.1111/nhs.12593 · Cited by 26
Depression in Heart Failure: A Systematic Review.
Ishak, W. W., Edwards, G., Herrera, N., Lin, T., Hren, K., Peterson, M., Ngor, A., Liu, A., Kimchi, A., Spiegel, B., et al. (2020) · PubMed Central · Cited by 26
Relation Between Plasma Ceramides and Cardiovascular Death in Chronic Heart Failure: A Subset Analysis of the GISSI-HF Trial
Targher, G., Lunardi, G., Mantovani, A., Meessen, J. M. T. A., Bonapace, S., Temporelli, P. L., Nicolis, E., Novelli, D., Conti, A., Tavazzi, L., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12885 · Cited by 25
“That said, in this hypothesis-generating study, we have supposed that there is a significant association between higher plasma levels of specific ceramides (that have been previously associated with higher risk of adverse cardiovascular outcomes in patients with CAD) and the risk of cardiovascular mortality also in pa…”
Background
Multifractal Detrended Fluctuation Analysis of Congestive Heart Failure Disease Based on Constructed Heartbeat Sequence
Li, S. (2020) · IEEE Access · doi:10.1109/access.2020.3037080 · Cited by 26
“Despite the great progress in diagnosis and treatment, morbidity and mortality are still high, and the prevalence is rising [2].”
Background
Unconventional Natural Gas Development and Hospitalization for Heart Failure in Pennsylvania
McAlexander, T. P., Bandeen‐Roche, K., Buckley, J. P., Pollak, J., Michos, E. D., McEvoy, J. W., & Schwartz, B. S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.023 · Cited by 27
Phosphatidylserine Supplementation as a Novel Strategy for Reducing Myocardial Infarct Size and Preventing Adverse Left Ventricular Remodeling
Schumacher, D., Curaj, A., Staudt, M., Cordes, F., Dumitrașcu, A.-R., Rolles, B., Beckers, C., Soppert, J., Rusu, M., Simsekyilmaz, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094401 · Cited by 26
“Infarct size and resultant cardiac function are the major determinants of post-infarct heart failure [1,2], a condition which exerts a huge global burden on healthcare and economic resources [3,4].”
Background
Health-Related Quality of Life Among Heart Failure Patients Attending an Outpatient Clinic in the University of Gondar Comprehensive Specialized Hospital Northwest, Ethiopia, 2020: Using Structural Equation Modeling Approach
Tarekegn, G. E., Gezie, L. D., Birhan, T. Y., & Ewnetu, F. (2021) · Patient Related Outcome Measures · doi:10.2147/prom.s322421 · Cited by 26
The Function of SUMOylation and Its Critical Roles in Cardiovascular Diseases and Potential Clinical Implications
Du, C., Chen, X., Su, Q., Lu, W., Wang, Q., Yuan, H., Zhang, Z., Wang, X., Wu, H., & Qi, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910618 · Cited by 26
Management of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 31
Transcatheter Left Ventricular Restoration in Patients With Heart Failure
Hamid, N. B., Jorde, U. P., Reisman, M., Latib, A., Lim, D. S., Joseph, S. M., Кurlianskaya, A., Polonetsky, O., Neužil, P., Reddy, V. Y., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.003 · Cited by 26
Lifetime prediction of coronary heart disease and heart disease of uncertain etiology in a 50-year follow-up population study
Menotti, A., & Puddu, P. E. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.151 · Cited by 26
“Most information on the relationship with risk factors can indirectly be found in contributions generically referring to heart failure [20–26].”
Background
Predictors of medication nonadherence differ among black and white patients with heart failure
Dickson, V. V., Knafl, G. J., & Riegel, B. J. (2015) · Research in Nursing & Health · doi:10.1002/nur.21663 · Cited by 26
Myocardial tissue engineering for cardiac repair
Pecha, S., Eschenhagen, T., & Reichenspurner, H. C. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.12.007 · Cited by 26
Carbon monoxide releasing molecule improves structural and functional cardiac recovery after myocardial injury
Segersvärd, H., Lakkisto, P., Hänninen, M., Forstén, H., Sirén, J., Immonen, K., Kosonen, R., Sarparanta, M. P., Laine, M., & Tikkanen, I. T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.031 · Cited by 26
Effects of chronically increased VEGF‐A on the aging heart
Marneros, A. G. (2017) · The FASEB Journal · doi:10.1096/fj.201700761rr · Cited by 26
“Heart failure is among the most common causes of hospitalization among the elderly (1).”
Background
Therapeutic inhibition of galectin‑3 improves cardiomyocyte apoptosis and survival during heart failure
Li, X., Tang, X., Lu, J., & Yuan, S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8323 · Cited by 26
“The prevalence of HF is expected to rise due to the aging population and improved treatment of cardiovascular diseases that precede HF (5).”
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake–Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats
Namai-Takahashi, A., Sakuyama, A., Nakamura, T., Miura, T., Takahashi, J., Kurosawa, R., Kohzuki, M., & Ito, O. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy143 · Cited by 26
Ischemic Cardiomyopathy Affects the Thioredoxin System in the Human Myocardium
Neidhardt, S., Garbade, J., Emrich, F. C., Klaeske, K., Borger, M. A., Lehmann, S., Jawad, K., & Dieterlen, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.01.017 · Cited by 26
Engineered Electrospun Polyurethane Composite Patch Combined with Bi-functional Components Rendering High Strength for Cardiac Tissue Engineering
Mani, M., Jaganathan, S. K., Faudzi, A. A. M., & Sunar, M. S. (2019) · Polymers · doi:10.3390/polym11040705 · Cited by 26
Intake of Different Dietary Proteins and Risk of Heart Failure in Men: The Kuopio Ischaemic Heart Disease Risk Factor Study
Virtanen, H. E. K., Voutilainen, S., Koskinen, T. T., Mursu, J., Tuomainen, T.-P., & Virtanen, J. K. (2018) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004531 · Cited by 27
Advances in Cardiac SPECT and PET Imaging: Overcoming the Challenges to Reduce Radiation Exposure and Improve Accuracy
Small, G. R., Wells, R. G., Schindler, T. H., Chow, B. J. W., & Ruddy, T. D. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.10.003 · Cited by 25
‘Prognostic implications of non-culprit plaques in acute coronary syndrome: non-invasive assessment with coronary CT angiography’
Dedic, A., Kurata, A., Lubbers, M. M., Meijboom, W. B., van Dalen, B. M., Snelder, S. M., Korbee, R. S., Moelker, A. D., Ouhlous, M., van Domburg, R., et al. (2016) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jew002 · Cited by 25
Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation
Banerjee, A., Fauchier, L., Bernard-Brunet, A., Clémenty, N., & Lip, G. Y. H. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-12-1033 · Cited by 25
The effectiveness of the use of consumer health information technology in patients with heart failure: A meta-analysis and narrative review of randomized controlled trials
Or, C. K., Tao, D., & Wang, H. (2016) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x15625540 · Cited by 25
Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice
Du, A., Westerhout, C. M., McAlister, F. A., Shanks, M., Oudit, G. Y., Paterson, D. I., Hanninen, M., Thomas, J., & Ezekowitz, J. A. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000643 · Cited by 25
Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure
Mastorci, F., Sabatino, L., Vassalle, C., & Pingitore, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00927 · Cited by 24
Impact of Remote Titration Combined With Telemonitoring on the Optimization of Guideline-Directed Medical Therapy for Patients With Heart Failure: Internal Pilot of a Randomized Controlled Trial
Artanian, V., Ross, H. J., Rac, V. E., O'Sullivan, M., Brahmbhatt, D. H., & Seto, E. (2020) · JMIR Cardio · doi:10.2196/21962 · Cited by 25
“There were more men than women in both groups, which is typical for HFrEF clinics, and the average age of the participants was notably lower than the general HF patient population [28] but was representative of the clinic where the study was conducted.”
Result
Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden
Boman, K., Lindmark, K., Stålhammar, J., Olofsson, M., Costa‐Scharplatz, M., Fonseca, A. F., Johansson, S., Heller, V., Törnblom, M., & Wikström, G. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053806 · Cited by 25
The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation
Goerlich, C. E., Singh, A. K., Griffith, B. P., & Mohiuddin, M. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00112-x · Cited by 25
Dual Medicare and Veteran Health Administration Use and Ambulatory Care Sensitive Hospitalizations
Ajmera, M., Wilkins, T. L., & Sambamoorthi, U. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1788-4 · Cited by 25
Association Between Male Sex and Increased Mortality After Falls
Nakada, T., Nakao, S., Mizushima, Y., & Matsuoka, T. (2015) · Academic Emergency Medicine · doi:10.1111/acem.12677 · Cited by 25
Ivabradine
Chaudhary, R., Garg, J., Krishnamoorthy, P. M., Shah, N. N., Lanier, G. M., Martinez, M. W., & Freudenberger, R. S. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415624157 · Cited by 26
“Mortality associated with HF reaches as high as 250,000 per year in the United States alone.(1) The current treatment options for the management of HF include beta-blockers, angiotensinconverting enzyme inhibitors or angiotensin-receptor blockers (ARBs), diuretics, aldosterone receptor blockers, and the most recently…”
Background
Tricuspid valve repair in patients with left-ventricular assist device implants and tricuspid valve regurgitation: propensity score-adjusted analysis of clinical outcome
Oezpeker, C., Zittermann, A., Paluszkiewicz, L., Piran, M., Puehler, T., Sayin, A. O., Ensminger, S. M., Milting, H., Morshuis, M., & Gummert, J. F. (2015) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivv260 · Cited by 25
“The disease affects more than 23 million people globally and is associated with significant morbidity and mortality [2].”
Background
Forensic Analysis Reveals Acute Decompensation of Chronic Heart Failure in a 3500‐Year‐Old Egyptian Dignitary
Bianucci, R., Loynes, R. D., Sutherland, M. L., Lallo, R., Kay, G. L., Froesch, P., Pallen, M. J., Charlier, P., & Nerlich, M. L. (2016) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13138 · Cited by 25
“Currently, 20 million people worldwide are affected by chronic left heart failure who are mainly over 65 and have a poor prognosis (9).”
Background
Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure
Deng, W., Ednie, A. R., Qi, J., & Bennett, E. S. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0574-1 · Cited by 25
“Heart failure (HF) affects more than 23 million people worldwide [12], with dilated cardiomyopathy (DCM) the third most common cause of HF.”
Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload
Li, W., Zhao, Y., Zhu, G., Peng, W., Zhu, M., Yu, X., Chen, W., Xu, D., & Xu, Y. (2016) · Clinical Science · doi:10.1042/cs20160664 · Cited by 24
Cardiac BIN1 (cBIN1) is a regulator of cardiac contractile function and an emerging biomarker of heart muscle health
Zhou, K., & Hong, T. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0249-x · Cited by 26
“Heart failure (HF), a common end-stage syndrome of different cardiac diseases, affects millions of people worldwide (Bui et al., 2011).”
Background
Impaired peripheral vasodilation during graded systemic hypoxia in healthy older adults: role of the sympathoadrenal system
Richards, J. C., Crecelius, A. R., Larson, D. G., Luckasen, G. J., & Dinenno, F. A. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00794.2016 · Cited by 25
“Systemic hypoxia is, not only a physiological stressor, but may also be a significant pathophysiological stressor observed in disease states, such as obstructive sleep apnea and congestive heart failure, both of which increase in prevalence with advancing age (4, 7).”
Using nationwide ‘big data’ from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the ClinicAl disease research using LInked Bespoke studies and Electronic health Records (CALIBER) programme
Hemingway, H., Feder, G. S., Fitzpatrick, N. K., Denaxas, S., Shah, A. D., & Timmis, A. (2017) · Programme Grants for Applied Research · doi:10.3310/pgfar05040 · Cited by 27
Ivabradine: Current and Future Treatment of Heart Failure
Thorup, L., Simonsen, U., Grimm, D. G., & Hedegaard, E. R. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12784 · Cited by 25
Correlations between stress, anxiety and depression and sociodemographic and clinical characteristics among outpatients with heart failure
Cirelli, M. A., Lacerda, M. S., Lopes, C. T., Lopes, J. D. L., & de Barros, A. L. B. L. (2017) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2017.11.008 · Cited by 25
Nanotized PPARα Overexpression Targeted to Hypertrophied Myocardium Improves Cardiac Function by Attenuating the p53-GSK3β-Mediated Mitochondrial Death Pathway
Rana, S., Datta, R., Chaudhuri, R. D., Chatterjee, E., Chawla‐Sarkar, M., & Sarkar, S. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7371 · Cited by 25
Air pollution and diastolic function in elderly women – Results from the SALIA study cohort
Ohlwein, S., Klümper, C., Vossoughi, M., Sugiri, D., Stolz, S., Vierkötter, A., Schikowski, T., Kara, K., Germing, A., Quaß, U., et al. (2016) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2016.02.006 · Cited by 25
Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey
Filippatos, G. S., Farmakis, D. T., Bistola, V., Karavidas, A. I., Mebazaa, A., Maggioni, A. P., & Parissis, J. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614527012 · Cited by 24
Regenerative medicine for the treatment of heart disease
Hansson, E. M., & Lendahl, U. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12033 · Cited by 25
Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: A systematic review
Seco, M., Zhao, D. F., Byrom, M. J., Wilson, M. K., Vallely, M. P., Fraser, J. F., & Bannon, P. G. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.137 · Cited by 24
Clinical characteristics and long-term prognosis of ischemic and non-ischemic cardiomyopathy
Zhang, Z., Meng, F., Hou, X., Qian, Z., Wang, Y., Qiu, Y., Jiang, Z.-Y., Du, A.-J., Qin, C., & Zou, J. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.04.004 · Cited by 24
“Antiplatelet agents; Anticoagulants; Nitrates; Statins; Calcium antagonist (CCB); Antiarrhythmia drugs (6) Device implantation and other novel therapy: pacemaker; ICD; CRT/D; Heart transplantation.”
Background
Runt‐related transcription factor 1 (Runx1) aggravates pathological cardiac hypertrophy by promoting p53 expression
Zhang, D., Liang, C., Li, P., Yang, L., Hao, Z., Kong, L., Tian, X., Guo, C., Dong, J., Zhang, Y., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16704 · Cited by 24
β-elemene blocks lipid-induced inflammatory pathways via PPARβ activation in heart failure
Shao, M., Wang, M., Ma, L., Wang, Q., Gao, P., Tian, X., Li, C., Lu, L., Li, C., Wang, W., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174450 · Cited by 24
Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 31
Trends in Heart Failure Clinical Trials From 2001–2012
Tahhan, A. S., Vaduganathan, M., Kelkar, A. A., Georgiopoulou, V. V., Kalogeropoulos, A. P., Greene, S. J., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.06.014 · Cited by 26
Self-citation
Quantitative Proteomics and Immunohistochemistry Reveal Insights into Cellular and Molecular Processes in the Infarct Border Zone One Month after Myocardial Infarction
Yang, L., Gregorich, Z. R., Cai, W., Zhang, P., Young, B., Gu, Y., Zhang, J. J., & Ge, Y. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00107 · Cited by 24
Identification and Validation of a Salivary Protein Panel to Detect Heart Failure Early
Zhang, X., Walsh, T., Atherton, J. J., Kostner, K., Schulz, B. L., & Punyadeera, C. (2017) · Theranostics · doi:10.7150/thno.21727 · Cited by 24
“HF presents a large social and economic burden due to a high global prevalence, affecting approximately 26 million people worldwide [2].”
Background
National Trends and Outcomes in Dialysis-Requiring Acute Kidney Injury in Heart Failure: 2002–2013
Correa, A. A., Patel, A., Chauhan, K., Shah, H., Saha, A., Dave, M., Poojary, P., Mishra, A., Annapureddy, N., Dalal, S., et al. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.05.001 · Cited by 24
Predictive Systems: Role of Feature Selection in Prediction of Heart Disease
Panda, D., Ray, R., Abdullah, A. A., & Dash, S. R. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1372/1/012074 · Cited by 24
“Heart Disease has been identified as one of the most alarming factors causing untimely deaths worldwide [1].”
Background
Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View
Komici, K., Conti, V., Davinelli, S., Bencivenga, L., Rengo, G., Filippelli, A., Ferrara, N., & Corbi, G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2176728 · Cited by 24
“USA [9], with higher prevalence in advanced age.”
BackgroundInfluential
Utility of the Nutritional Screening in Predicting Adverse Outcome of Patients With Overweight/Obesity and Acute Heart Failure
Uemura, Y., Shibata, R., MASUDA, A., KATSUMI, Y., Takemoto, K., Koyasu, M., Ishikawa, S., Mitsuda, T., Murohara, T., & Watarai, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.02.005 · Cited by 24
Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
Nakajima, K., Nakata, T., Doi, T., Kadokami, T., Matsuo, S., Konno, T., Yamada, T., & Jacobson, A. F. (2018) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jey016 · Cited by 24
“Chronic heart failure (CHF) is a life-threatening condition affecting approximately 26 million people worldwide, and heart failure carries substantial risk of morbidity and mortality.(1) Recent advances in non-pharmacological treatment, including device therapy, can improve quality of life and survival in CHF patients.”
Background
Physical Capacity in LVAD Patients: Hemodynamic Principles, Diagnostic Tools and Training Control
Reiss, N., Schmidt, T., Workowski, A., Willemsen, D., Schmitto, J. D., Haverich, A., & Bjarnason‐Wehrens, B. (2016) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000529 · Cited by 23
“The number of people affected will continue to increase steeply, especially in the elderly segment of the population (1, 2).”
Background
Incidence and variables associated with short and long-term mortality in patients with systemic lupus erythematosus and sepsis admitted in intensive care units
Abramovich, E., Barrett, O., Dreiher, J., Novack, V., & Abu‐Shakra, M. (2018) · Lupus · doi:10.1177/0961203318796288 · Cited by 23
Impact of calculated plasma volume status on all-cause and cardiovascular mortality: 4-year nationwide community-based prospective cohort study
Otaki, Y., Watanabe, T., Konta, T., Watanabe, M., Asahi, K., Yamagata, K., Fujimoto, S., Tsuruya, K., Narita, I., Kasahara, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237601 · Cited by 23
“Heart failure remains a major and increasing public health problem, with a high mortality rate [4].”
Background
Predicting cardiac disease from interactions of simultaneously-acquired hemodynamic and cardiac signals
Fathieh, F., Paak, M., Khosousi, A., Burton, T., Sanders, W. E., Doomra, A., Lange, E., Khedraki, R., Bhavnani, S. P., & Ramchandani, S. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.105970 · Cited by 23
Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
Teo, Y. H., Yoong, C. S. Y., Syn, N. L. X., Teo, Y. N., Cheong, J. Y. A., Lim, Y. C., Lee, C., Yeo, T., Chai, P., Wong, R. C.-C., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03147-4 · Cited by 23
“In a sensitivity analysis of SGLT2 inhibitors in trials with follow-up durations of ≥ 1 year, Nassif 2019 [37] (DEFINE-HF trial) and Damman 2020 [24] (EMPARESPONSE-AHF trial) were excluded as their followup durations were 13 weeks and 60 days respectively.”
Background
Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction
Sun, Y., Si, J., Li, J., Dai, M., King, E., Zhang, X., Zhang, Y., Xia, Y., Tse, G., & Liu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.656536 · Cited by 23
“D-Dimer (ug/ml) 570 (270, 1,210) 400 (230, 755) 525 (250, 1,215) 660 (388, 1,598) 0.”
BackgroundMethod
OTUD7B (Cezanne) ameliorates fibrosis after myocardial infarction via FAK-ERK/P38 MAPK signaling pathway
Zhang, J., Zha, Y., Jiao, Y., Li, Y., Wang, J., & Zhang, S. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109266 · Cited by 24

Authors: Bui, A. L., Horwich, T. B., & Fonarow, G. C.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Fonarow, Gregg C.
ORCID: Horwich, Tamara B.
Fonarow, Gregg C.
Venue: Nature Reviews Cardiology
Publisher: Springer Science and Business Media LLC
Published: 2010-11-09
Volume: 8
Issue: 1
Pages: 30-41
ISSN: 1759-5002 (ISSN-L)
1759-5010
DOI: 10.1038/nrcardio.2010.165
PMC: PMC3033496
OpenAlex: W1992644002
Cited by: 2,077
References: 144
Citations by year: 2026: 48 · 2025: 91 · 2024: 126 · 2023: 158 · 2022: 173 · 2021: 186 · 2020: 209 · 2019: 169 · 2018: 191 · 2017: 211 · 2016: 174 · 2015: 121 · 2014: 91 · 2013: 60 · 2012: 46
FWCI: 6.84
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Cardiology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Heart Failure Society of America
Ahmanson Foundation
National Institutes of Health (5k23hl085097-04)
National Heart, Lung, and Blood Institute (1K23HL085097, K23 HL085097, T32HL007895)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords: heart failure, heart failure epidemiology, heart failure risk factors, heart failure prevalence, heart failure mortality, health care costs, ischemic heart disease, hypertension, smoking, obesity, diabetes mellitus
MeSH terms: Adult, Aged, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Incidence, Prevalence, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology and risk profile of heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks